Amicus Therapeutics (FOLD)
Amicus Therapeutics Earnings Per Share Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About EPS Growth
YCharts EPS growth rates are calculated as quarterly year on year growth rates.
EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. EPS growth rates help investors identify stocks that are increasing or decreasing in profitability.
If a company has an EPS of $5.00 in 2008 and EPS of $6.00 in 2009, the company has an EPS growth rate of $6.00/$5.00 - 1 = 20% during fiscal year 2009.
Learn More
You may also be interested in these FOLD related companies
FOLD News
Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Encouraged on Upcoming Data
May 11, 9:50AM Street Insider
May 11, 9:50AM Street Insider
Listen to $FOLD Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3mFn
about 19 days ago by earningscast
about 19 days ago by earningscast
Amicus Therapeutics to Announce First Quarter 2012 Financial Results on May 10, 2012
May 04, 10:00AM GlobeNewswire
May 04, 10:00AM GlobeNewswire
$FOLD http://stks.co/3Lqx Long setup. Bullish engulfing. 200MA support.
about 44 days ago by VexTrades
about 44 days ago by VexTrades
$FOLD--Some huge insider buys just came through at 5.70. Do your own research. This looks like a stock offering, but insiders are buying.
about 81 days ago by MicroInsider
about 81 days ago by MicroInsider
Amicus Therapeutics (FOLD) Closes 10M Offering; Nets Proceeds of $62M
Mar 07, 10:16AM Street Insider
Mar 07, 10:16AM Street Insider
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Over-Allotment Option
Mar 07, 10:15AM GlobeNewswire
Mar 07, 10:15AM GlobeNewswire
$FOLD forms bearish "Head and Shoulders Top" chart pattern. http://stks.co/2hZy
about 83 days ago by RecogniaEvents
about 83 days ago by RecogniaEvents
$ECTE i see great potential in this one. A skin glucose monitor with no sticks!! Also long $FOLD for a long term play...
about 87 days ago by Stuckinstock
about 87 days ago by Stuckinstock
From Earlier: Amicus Therapeutics Prices Underwritten Offering of 10M Shares at $5.70
Mar 02, 8:30AM Benzinga
Mar 02, 8:30AM Benzinga
$FOLD Announces Proposed Public Offering of Common Stock; No Amount Given
about 89 days ago by Benzinga
about 89 days ago by Benzinga
Amicus Therapeutics Announces Proposed Public Offering of Common Stock; No Amount Given
Mar 01, 4:01PM Benzinga
Mar 01, 4:01PM Benzinga
Amicus Therapeutics to Present at 2012 RBC Global Healthcare Conference
Feb 28, 11:08AM GlobeNewswire
Feb 28, 11:08AM GlobeNewswire
Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Management Dinner Takeaways
Feb 23, 10:16AM Street Insider
Feb 23, 10:16AM Street Insider
Canaccord Genuity Reiterates a 'Hold' on Amicus Therapeutics (FOLD); Q4/11 Update: Market Focus Shifts to Combo Therapy
Feb 14, 9:06AM Street Insider
Feb 14, 9:06AM Street Insider
Listen to $FOLD Q4 2011 earnings call (EPS -0.25 vs est -0.37) - live at 05:00 PM, ondemand after - http://stks.co/2Nmy
about 106 days ago by earningscast
about 106 days ago by earningscast
Amicus Therapeutics Announces Fourth Quarter and Full-Year 2011 Financial Results
Feb 13, 4:01PM GlobeNewswire
Feb 13, 4:01PM GlobeNewswire
10:50EST $FOLD Up 8% for the day. Reporting Earnings Today. http://stks.co/2NKe #tradeideas #stocks #investing #earnings
about 106 days ago by TradeIdeas1
about 106 days ago by TradeIdeas1
Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); WORLD 2012: ERT Combo Proof of Concept
Feb 13, 8:47AM Street Insider
Feb 13, 8:47AM Street Insider
Amicus Therapeutics (FOLD) Reports Patient Screening Profiles From Phase 3 Fabry Study
Feb 13, 7:36AM Street Insider
Feb 13, 7:36AM Street Insider
Amicus Therapeutics Presents Patient Screening Profiles From Phase 3 Fabry Study
Feb 13, 7:31AM Benzinga
Feb 13, 7:31AM Benzinga
$FOLD Presents Preclinical Studies for Gaucher Disease; AVI BioPharma Results From Phase I Clinical Trial. http://stks.co/2LHx
about 109 days ago by abubnic
about 109 days ago by abubnic
$FOLD filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/nqC
about 216 days ago by MarketBrief
about 216 days ago by MarketBrief
$FOLD $6.01 Crowley John F director officer (Executive Chairman) P 20,000 @ $6.04 amnt $120,800 proc'd ($600) 6/17/2011
about 343 days ago by canarionyc
about 343 days ago by canarionyc
$FOLD $7.56 Valenzano Ken officer (VP, Pharmacology & Biology) S 2,250 @ $7.50 amnt $16,875 proc'd ($135) 5/24/2011
about 370 days ago by canarionyc
about 370 days ago by canarionyc
Register for BioNJ's annual meeting held 1/27/11, featured speaker J. Crowley, Amicus $FOLD CEO. Register at http://bit.ly/hxEerO #BioNJADM
about 515 days ago by MDBpartners
about 515 days ago by MDBpartners
Best Stock List recommended $FOLD -Amicus Therapeutics, Inc. on 10/25/2010 16:00:00 and has gained 4.13%! $SPY http://bit.ly/gvoEjM
about 516 days ago by Tieler
about 516 days ago by Tieler
Best Stock List recommended $FOLD -Amicus Therapeutics, Inc. on 10/25/2010 16:00:00 and has gained 4.13%! $SPY http://bit.ly/hLiIKn
about 516 days ago by Tieler
about 516 days ago by Tieler
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FOLD | 4.91 | -0.08 | -1.60% | 222.80M |
| FOH | 0.37 | +0.00 | +0.00% | 14.40M |
| FOF | 12.20 | +0.11 | +0.91% | |
| FOE | 4.64 | +0.06 | +1.31% | 396.49M |
| FNSR | 15.08 | +0.49 | +3.36% | 1.325B |
| FLY | 12.35 | +0.03 | +0.24% | 316.01M |
| FLXS | 20.04 | +0.05 | +0.25% | 135.13M |
| FLT | 38.37 | -0.09 | -0.23% | 3.181B |
| FLR | 50.40 | +0.70 | +1.41% | 8.422B |
| FLOW | 3.05 | -0.02 | -0.65% | 146.93M |
